-- Zydus Lifesciences (NSE:ZYDUSLIFE, BOM:532321) received seven observations from the US Food and Drug Administration (US FDA) following the inspection of its Unit 9 facility located at Zydus Biotech Park in Ahmedabad, India, according to a Wednesday filing to the India stock exchanges.
The regulator inspected the Ahmedabad unit from April 27 to May 5.
The company plans to closely work with the USFDA for work on resolving the observations expeditiously.
The company's shares were up nearly 3% in recent trade.